



**Zeltia Group announces results for the first 9 months 2014 with EBITDA of 25.6 million euro (+17.7%) and net income of 17.5 million euro (+24.3%)**

- **Revenues increased by +7%, to 117 million euro, with growth in sales of Yondelis<sup>®</sup> (+8%) and in Consumer Chemicals (+8%).**
- **Group EBITDA expanded by +17.7%, to 25.6 million euro, to which the oncology area contributed 29.1 million euro (+12%).**
- **Total net debt has been cut by 11% since the beginning of the year.**

**Madrid, 30 October 2014:** Zeltia Group (Grupo Zeltia, ZEL.MC) announces its financial and corporate results for the first 9 months of 2014. Zeltia's net sales amounted to 117 million euro in the first nine months of 2014, up 7% with respect to the same period last year. Sales expanded during the period in both Biopharmaceuticals, with 61.2 million euro (+7%), and Consumer Chemicals, with 57.4 million euro (+8%). Within the Biopharmaceutical area, Yondelis<sup>®</sup> sales amounted to 57.4 million euro, i.e. an increase of 8% with respect to the same period last year.

Grupo Zeltia's EBITDA amounted to 25.6 million euro in the first nine months of 2014, an 18% increase year-on-year. The main contributor to EBITDA was the oncology business, with 29 million euro (25.9 million euro in 9M13).

EBITDA increased despite greater R&D spending on the various trials with compound PM1183 and on the Phase III registration trial with Aplidin<sup>®</sup> in multiple myeloma, for which recruitment is advancing at a good pace.



Grupo Zeltia's attributable net profit amounted to 17.5 million euro in 9M14, compared with 14.1 million euro in 9M13 (+24.3%).

The group's net interest-bearing debt improved by 11% with respect to the beginning of the year, and its cash position amounted to 37.3 million euro.

#### **About Zeltia**

Zeltia S.A. is a world-leading biopharmaceutical company specialised in the development of marine-based drugs for use in oncology. Zeltia Group consists mainly of the following companies: PharmaMar, the world-leading biotechnology company in advancing cancer care through the discovery and development of innovative marine-derived medicines; Genómica, Spain's leading molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi); and a chemical division comprising Zelnova and Xylazel, two highly profitable companies that are leaders in their respective market segments.

**For more information +34 91 444 4500**

This note is also available on the Zeltia web site: [www.zeltia.com](http://www.zeltia.com)